

Half Year Report Six months ended 30 June 2021

Sydney Australia, Monday 30 August 2021: Next Science Limited (ASX:NXS) (**Next Science**) today announces its Half Year Report for the six months ended 30 June 2021.

Highlights:

- 1H Revenue US\$3.9M (271% growth on prior half year)
- Gross Profit increased 234% on prior half year
- EBIT improved 38% on prior half year
- Cash on hand US\$13.2M
- XPerience™ No Rinse Antimicrobial Solution 510(k) process cleared by the FDA & VAC submissions commenced
- BlastX™ sales returned to Next Science & sales growing
- TGA Approval for BlastX in Australia

Key Activities

Next Science researches, develops and commercialises products which are based on its proprietary Xbio™ technology to resolve the issues caused by biofilms and their incumbent bacteria, fungi and viruses and the infections they cause in relation to human health. Next Science commercialises its technologies through a range of methods including licensing, product distribution partnerships, direct sales and product distribution via a network of independent sales representatives.

Managing Director, Judith Mitchell, commented: "Our 1H2021 results have been a record for Next Science in our short history. We are pleased with the current trajectory of the business and look forward to reporting the further success of our products in the marketplace, boosted by the addition of XPerience™ to our product offering.

Our ambition is for our products to become the standard of care in the majority of open surgeries.

Every day we are driven by the knowledge that our products are needed in every hospital. Our responsibilities are to ensure these hospitals know that our solutions are available and provide support as they increasingly use our products. It is well documented that infection is expensive to treat and can be fatal. We believe we can demonstrate how our products can decrease the overall cost of treatment by reducing infection rates and complications, improving patient outcomes and in turn saving patient lives."

Further Information:

Judith Mitchell

Managing Director, Next Science Limited
Phone: +61 2 8607 5124
Email: investorqueries@nextscience.com

Michael Brown

Pegasus Advisory
Phone: +61 400 248 080
Email: mbrown@pegasusadvisory.com.au

Approved and authorised for release by the Board of Directors.

NEXT SCIENCE®

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary Xbio technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. For further information visit: www.nextscience.com

Forward looking statements

This announcement may contain forward looking statements which may be identified by words such as "believes", "considers", "could", "estimates", "expects", "intends", "may" and other similar words that involve risks and uncertainties. Such statements are not guarantees of future performance and involved known and unknown risks uncertainties, assumptions and other important factors, many of which are beyond the control of Next Science or its Directors and management, and could cause Next Science's actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.